Post-earnings recap
Reported
Thu, Feb 22, 2018
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
75%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
BioMarin Pharmaceuticals reported a loss per share that was significantly worse than expected, which contributed to a slight decline in stock price. The lack of revenue details and forward guidance may raise concerns among investors about the company's near-term prospects. The stock's minor drop of 0.25% reflects cautious sentiment in light of these results.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.30 | N/A | -129.16% |
| Revenue | N/A | N/A | N/A |
Management expressed concerns about the current financial performance and reiterated their commitment to research and development. They did not provide specific guidance for future quarters.
Management highlighted ongoing challenges in achieving profitability.
They emphasized the need for continued investment in R&D to support future growth.
No specific updates were provided regarding product launches or pipeline progress.